Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.67. Xtant Medical shares last traded at $0.61, with a volume of 25,953 shares trading hands.

Wall Street Analyst Weigh In

Separately, Craig Hallum set a $1.50 target price on Xtant Medical and gave the stock a “buy” rating in a research note on Friday, October 18th.

Xtant Medical Stock Performance

The company has a market capitalization of $84.80 million, a PE ratio of -4.69 and a beta of 0.35. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%. The company had revenue of $27.94 million during the quarter.

Institutional Investors Weigh In On Xtant Medical

An institutional investor recently bought a new position in Xtant Medical stock. Evernest Financial Advisors LLC purchased a new position in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 40,000 shares of the medical device company’s stock, valued at approximately $27,000. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.